Integration of transcriptomics, proteomics and loss-of-function screening reveals WEE1 as a target for combination with dasatinib against proneural glioblastoma.
Alhalabi OT, Göttmann M, Gold MP, Schlue S, Hielscher T, Iskar M, Kessler T, Hai L, Lokumcu T, Cousins CC, Herold-Mende C, Heßling B, Horschitz S, Jabali A, Koch P, Baumgartner U, Day BW, Wick W, Sahm F, Krieg SM, Fraenkel E, Phillips E, Goidts V.
Alhalabi OT, et al. Among authors: koch p.
Cancer Lett. 2024 Nov 28;605:217265. doi: 10.1016/j.canlet.2024.217265. Epub 2024 Sep 25.
Cancer Lett. 2024.
PMID: 39332586
Free article.